Regen Biopharma, Inc.
0.0150+0.00 (+0%)
Oct 28, 4:00:00 PM EDT · OTC Markets OTCPK · RGBP · USD
Key Stats
Market Cap
473.32KP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Consulting deals for HemaXellerate trial
Regen Biopharma inked consulting pacts on October 2, 2025, with Dr. Harry Lander and CEO David Koos, each netting 20 million restricted common shares that vest only upon HemaXellerate's Phase I trial success. These deals lock in expertise for the stem cell therapy's safety and efficacy push in drug-refractory aplastic anemia patients, running through October 2028 or trial wrap. Shares dilute the 79.4 million outstanding pool. Forfeiture hits if the consulting ends early.
10-Q
Q3 FY2025 results
Regen Biopharma held net revenue steady at $59,065 for Q3 FY2025 ended June 30, 2025, matching last year, while YTD revenue ticked up 0.001% to $177,195 from licensing deals with related parties like Zander Therapeutics. Operating loss narrowed sharply y/y to $40,756 from $107,966, thanks to zero R&D spend and a 51.2% drop in consulting fees, yet net loss widened 28.6% to $167,292, driven by a $89,259 derivative expense from convertible notes. Cash edged up to $1,761 on $224,631 in related-party borrowings, but operating cash burn eased to $223,586 from $544,247; free cash flow not disclosed in the 10-Q. Convertible notes ballooned to $769,905 amid new issuances, while equity deficit deepened to $5.8 million. FDA approval hurdles loom large for its early-stage regenerative therapies.
8-K
Regen issues discounted convertible note
Regen Biopharma secured $85,000 in funding on August 5, 2025, via a $100,000 principal 6% convertible promissory note to Labrys Fund II LP, carrying a $15,000 original issue discount and maturing August 5, 2026. The note converts at 60% of the lowest trading price over the prior 20 days, potentially diluting shareholders amid the biotech's cash needs. Prepayment is restricted early on with escalating premiums up to 125%. Dilution looms large.
8-K
Convertible note funding issued
Regen Biopharma secured $117,000 in funding by issuing a $130,000 6% convertible promissory note to CFI Capital on July 28, 2025, with a $13,000 original issue discount and maturity on July 28, 2026. The note converts after six months at 60% of the lowest OTC trading price over 20 days, potentially diluting shareholders amid cash needs. This boosts liquidity but risks heavy dilution. Reserves 15.7 million shares for conversions.
8-K
CEO salary settled via shares
Regen Biopharma issued 10,000,000 common shares to CEO David Koos on June 10, 2025, settling $50,000 of his accrued salary from a 2015 employment agreement covering services through January 2020. This partial payment addresses $457,113.19 in total outstanding obligations, boosting outstanding shares to 31,554,704. The move clears immediate debt but dilutes equity holders.
IPO
Employees
Sector
Industry
AURX
Nuo Therapeutics, Inc.
2.29+0.00
BCDA
BioCardia, Inc.
1.31-0.06
FBLG
FibroBiologics, Inc.
0.39-0.03
GBIO
Generation Bio Co.
5.57-0.22
IMA
ImageneBio, Inc.
8.79+0.09
REGN
Regeneron Pharmaceuticals, Inc.
652.91-1.57
RENB
Lunai Bioworks Inc.
1.42+0.00
RGNX
REGENXBIO Inc.
12.84-0.32
RMTG
Regenerative Medical Technology
0.05+0.00
XBIO
Xenetic Biosciences, Inc.
3.42-0.16